Brokerages predict that Equillium (NYSE:EQ) will report earnings per share (EPS) of ($0.36) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Equillium’s earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.27). Equillium posted earnings of ($0.30) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 20%. The company is expected to issue its next quarterly earnings results on Thursday, November 21st.
On average, analysts expect that Equillium will report full-year earnings of ($1.41) per share for the current year, with EPS estimates ranging from ($1.70) to ($1.09). For the next year, analysts anticipate that the business will report earnings of ($1.83) per share, with EPS estimates ranging from ($2.23) to ($1.34). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Equillium.
Equillium (NYSE:EQ) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.04.
A number of research analysts have recently commented on EQ shares. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Equillium in a research report on Tuesday, August 13th. Zacks Investment Research cut shares of Equillium from a “buy” rating to a “hold” rating in a research note on Friday, October 4th.
Shares of NYSE:EQ traded up $0.13 during midday trading on Tuesday, reaching $3.33. 8,213 shares of the company were exchanged, compared to its average volume of 31,126. Equillium has a fifty-two week low of $2.56 and a fifty-two week high of $19.69. The stock has a fifty day simple moving average of $3.65 and a two-hundred day simple moving average of $4.83.
A number of institutional investors and hedge funds have recently bought and sold shares of EQ. Edge Wealth Management LLC bought a new position in Equillium during the second quarter valued at about $40,000. Paloma Partners Management Co bought a new position in Equillium during the second quarter valued at about $117,000. Morgan Stanley grew its position in Equillium by 206.0% during the second quarter. Morgan Stanley now owns 6,389 shares of the company’s stock valued at $37,000 after buying an additional 4,301 shares during the period. Finally, Victory Capital Management Inc. grew its position in Equillium by 11.0% during the second quarter. Victory Capital Management Inc. now owns 1,468,727 shares of the company’s stock valued at $8,313,000 after buying an additional 145,346 shares during the period.
Equillium Company Profile
Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.
Recommended Story: Producer Price Index (PPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.